Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
Michael R. Bishop(University of Chicago), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Giovanna Andreola(European Institute of Oncology), Steven Le Gouill(Inserm), Yok‐Lam Kwong(Queen Mary Hospital), Mohamed A. Kharfan‐Dabaja(Jacksonville College), Antonia Müller(University Hospital of Zurich), Koji Kato(AbbVie (United States)), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Marie José Kersten(Hovon), Ulrich Jäger(Medical University of Vienna), Pere Barba(Universitat Autònoma de Barcelona), Monique C. Minnema(University Medical Center Utrecht), Martin Dreyling(German Cancer Research Center), Franck Morschhauser(Hôpital Claude Huriez), David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Joseph P. McGuirk(University of Kansas Medical Center), Evgeny Degtyarev(Universitat Autònoma de Barcelona), Emmanuel Bachy(Université Claude Bernard Lyon 1), Aisha Masood(Novartis (United States)), Peter Borchmann(Düsseldorf University Hospital), Martin Janz(Max Delbrück Center), Werner Rabitsch(Medical University of Vienna), Duncan Purtill(Fiona Stanley Hospital), Charalambos Andreadis(University of California, San Francisco), Catherine Thieblemont(Université Paris Cité), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Esther Hian Li Chan(Universitat Autònoma de Barcelona), Stephen J. Schuster(Hospital of the University of Pennsylvania), Nada Hamad(UNSW Sydney), Hideo Harigae(Tohoku University Hospital), Richard T. Maziarz(Oregon Health & Science University), Harald Holte(Oslo University Hospital), Armando Santoro(IRCCS Humanitas Research Hospital), Michael Dickinson(The University of Melbourne), Peter A. McSweeney(Mesoblast (United States)), Richard Greil, Christopher del Corral(490 BioTech (United States)), Ian W. Flinn(Tennessee Oncology), Rakesh Awasthi(Novartis (Switzerland)), Simon Newsome(Novartis (United Kingdom))
Cited by 532
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k